PressJanuary 30, 2023 Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
PressJanuary 26, 2023 Hebrew University’ Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment
PressJanuary 25, 2023 Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
PressJanuary 25, 2023 Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin
PressJanuary 20, 2023 Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum
PressJanuary 20, 2023 Filament Health Announces Clinical Trial Approval in Partnership With Psychiatric Centre Copenhagen
PressJanuary 20, 2023 Mydecine Innovation Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
PressJanuary 20, 2023 Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
